Several economic studies have reported the cost-effectiveness of SGLT2 inhibitors among adults with T2DM (Tzanetakos et al., 2016; Gourzoulidis et al., 2018; Rahman et al., 2018). Here, SLC5A2 is linked to type 2 diabetes mellitus.